Immunoelectron microscopic localization of the M6a antigen in rat brain

The monoclonal antibody M6-7, which recognizes both native and denatured immunopurified M6a antigen, was used in the present immunocytochemical study to localize its corresponding antigen in young rat brain. Strong labelling was observed in the cerebellar molecular layer, which corresponds to heavily stained axon terminals originating from granule cells. The immunodeposit, as observed by electron microscopy, is present only on the cytoplasmic side of the presynaptic membrane and on the membrane of synaptic vesicles. In contrast, the Purkinje cells and their processes are unstained. Stained synapses are also found, although less frequently, in several other cerebral areas. The pattern of staining at these synapses is similar to that observed in the cerebellar molecular layer. It is hypothesized, on the basis of its restricted distribution in certain neuronal endings and its high homology with myelin proteolipids, that the M6a antigen revealed by the M6-7 antibody is probably involved in a specific biological function in these structures.     

Incidence and definition of sepsis and associated organ dysfunction

AIMS: To discuss the incidence, outcome and predisposing factors to systemic inflammatory response syndrome (SIRS), sepsis, and multiple organ failure. METHODS: A qualitative review of the literature. RESULTS: Case definitions of sepsis and severe sepsis, though clarified recently, are still arbitrary. It seems, however, that SIRS is not useful in identifying severe sepsis while organ failure has become a cornerstone for this definition. Incidence of severe sepsis appears to be approximately 10% of all ICU admissions, totaling nearly one million cases annually in the U.S. alone, and rising. Mortality associated with these events is still high, especially among ICU patients. Recent studies have been demonstrating an association between a variety of genetic polymorphisms and progression to and dying from sepsis. CONCLUSION: Recently there has been an increasing amount of information enabling characterization of the epidemiology of sepsis, which may help to direct appropriate care in the coming years.     

Estrogen-mediated regulation of cholinergic expression in basal forebrain neurons requires extracellular-signal-regulated kinase activity

Beyond the role estrogen plays in neuroendocrine feedback regulation involving hypothalamic neurons, other roles for estrogen in maintaining the function of CNS neurons remains poorly understood. Primary cultures of embryonic rat neurons together with radiometric assays were used to demonstrate how estrogen alters the cholinergic phenotype in basal forebrain by differentially regulating sodium-coupled high-affinity choline uptake and choline acetyltransferase activity. High-affinity choline uptake was significantly increased 37% in basal forebrain cholinergic neurons grown in the presence of a physiological dose of estrogen (5 nM) from 4 to 10 days in vitro whereas choline acetyltransferase activity was not significantly changed in the presence of 5 or 50 nM estrogen from 4 to 10 or 10 to 16 days in vitro. Newly-synthesized acetylcholine was significantly increased 35% following 6 days of estrogen treatment (10 days in vitro). These effects are in direct contrast to those found for nerve growth factor; that is, nerve growth factor can enhance the cholinergic phenotype through changes in choline acetyltransferase activity alone. This is most surprising given that mitogen-activated protein kinase and extracellular-signal-regulated kinase1/2, kinases also activated in the signaling pathway of nerve growth factor, were found to participate in the estrogen-mediated changes in the cholinergic phenotype. Likewise, general improvement in the viability of the cultures treated with estrogen does not account for the effects of estrogen as determined by lactate dehydrogenase release and nerve growth factor-responsiveness. These findings provide evidence that estrogen enhances the differentiated phenotype in basal forebrain cholinergic neurons through second messenger signaling in a manner distinct from nerve growth factor and independent of improved survival.     

Resolution and conservation of mismatches in DNA end joining

DNA end joining is a major pathway for the elimination of double-strandbreaks from chromosomal DNA of higher eucaryotic cells. Extractsof Xenopus laevis eggs rejoin such breaks even when their shortsingle-stranded termini are expected to form imperfectly matchedoverlaps. However, end-joined products cloned in Escherichiacoli, necessarily give rise to perfectly matched products. Thereforeit has not been possible to determine whether the end joiningprocess creates mismatched products, perfectly matched (resolved)products or both. To investigate whether mismatch resolutionwas the result of the X. laevis end joining process or of activitiesof the bacterial host we used denaturing gradient gel electrophoresisto analyse joined products. We found that the end joining processdoes include mismatch resolution, the degree of which varieswith regard to the nature of the original overlap structure.Mismatches 3' to a gap are completely resolved, mismatches 3'to a nick and 5' to a nick or gap are resolved to some extentbut are generally conserved. Mismatches between base matchesare always conserved. These findings suggest competing processesof ligation, DNA fill-in synthesis or exonucleolytic excisionof mismatched bases next to a gap or nick. At mismatches 3'to a nick the probability of ligation is greater than that ofexcision while at mismatches 3' to a gap the probability ofexcision is greater than elongation of a given mismatch. Atmismatches 5' to nicks or gaps it appears that ligation or elongationand ligation, respectively, are the most probable pathways butproducts resulting from mismatch excision, elongation and ligationare also detected. ⁵To whom correspondence should be addressed     

Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer

In 1985 we presented results of a randomized trial involving 1843 women followed for five years that indicated that segmental breast resection (lumpectomy) followed by breast irradiation is appropriate therapy for patients with Stage I or II breast cancer (tumor size, less than or equal to 4 cm), provided that the margins of the resected specimens are free of tumor. Women with positive axillary nodes received adjuvant chemotherapy. Lumpectomy followed by irradiation resulted in a five-year survival rate of 85 percent, as compared with 76 percent for total mastectomy, a rate of survival free of distant disease of 76 percent, as compared with 72 percent, and a disease-free survival rate of 72 percent, as compared with 66 percent. In the current study, we have extended our observations through eight years of follow-up. Ninety percent of the women treated with breast irradiation after lumpectomy remained free of ipsilateral breast tumor, as compared with 61 percent of those not treated with irradiation after lumpectomy (P less than 0.001). Among patients with positive axillary nodes, only 6 percent of those treated with radiation and adjuvant chemotherapy had a recurrence of tumor in the ipsilateral breast. Lumpectomy with or without irradiation of the breast resulted in rates of disease-free survival (58 +/- 2.6 percent), distant-disease-free survival (65 +/- 2.6 percent), and overall survival (71 +/- 2.6 percent) that were not significantly different from those observed after total mastectomy (54 +/- 2.4 percent, 62 +/- 2.3 percent, and 71 +/- 2.4 percent, respectively). There was no significant difference in the rates of distant-disease-free survival (P = 0.2) or survival (P = 0.3) among the women who underwent lumpectomy (with or without irradiation), despite the greater incidence of recurrence of tumor in the ipsilateral breast in those who received no radiation. We conclude that our observations through eight years are consistent with the findings at five years and that these new findings continue to support the use of lumpectomy in patients with Stage I or II breast cancer. We also conclude that irradiation reduces the probability of local recurrence of tumor in patients treated with lumpectomy.     

人组织激肽释放酶基因对2型糖尿病大鼠血压的影响及机制

目的：探讨人组织激肽释放酶（HK）基因对2型糖尿病大鼠血压的影响及其机制。方法:高脂高糖饮食加小剂量链脲佐菌素建立2型糖尿病动物模型。以重组腺相关病毒为载体介导HK基因（HK组）或对照基因LacZ（LacZ组）在糖尿病大鼠体内表达，观察实验动物血压变化及离体主动脉对乙酰胆碱（Ach）依赖性血管舒张反应和一氧化氮（NO）、内皮素-1（ET-1）、内皮素受体A（ETA-R）表达。 结果:(1) HK组第2周开始出现血压下降，并一直持续到实验结束（12周时），而LacZ组血压无明显下降。(2) LacZ组离体主动脉对乙酰胆碱（Ach）依赖性血管舒张反应明显低于HK组。(3) HK组大鼠主动脉NO2-/NO3-浓度明显高于LacZ组，而ET-1和ETA-R mRNA明显低于LacZ组。 结论:重组腺相关病毒介导HK基因表达明显降低2型糖尿病大鼠血压，改善内皮依赖性血管舒张功能，原因可能与增加动脉NO释放，减少ET-1和ETA-R的表达有关。     

The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients

Various polymorphisms of the MDR1 gene that encodes for P-glycoprotein (P-gp), a transmembrane pump, have been identified. A silent mutation C3435T in exon 26 and a G2677T mutation in exon 21 have been correlated with P-gp expression and function in humans. The objectives of this study were (a) to determine whether the MDR1 exon 21 and exon 26 polymorphisms were related to steroid weaning in a pediatric heart transplant (HTx) population, and (b) to determine whether an association exist between the MDR1 exon 21 and exon 26 polymorphisms in these patients. Sixty-nine pediatric HTx patients were studied. MDR1 genotyping was determined by polymerase chain reaction amplification, sequencing the DNA, and sequence evaluation using Polyphred software (University of Washington) to identify genotypes. The steroid dose at 1 year post-transplantation was recorded. For steroid weaning at one year post-HTx for MDR1 C3435T, 12 of 18 (67%) patients in the CC genotype were still on prednisone, whereas only 18 of 47 (38%) of the CT/TT group were still receiving prednisone (p = 0.04). Similar results were observed for the MDR1 G2677T genotyping and steroid weaning. Forty-three of 46 patients (93.5%) who have MDR1 C3435T allele also have a mutant G2677T allele (p < 0.001). We conclude that (a) a significantly larger number of MDR1 3435 CC HTx patients remain on steroids at 1 year after transplantation, and (b) the MDR1 C3435T genotype is associated with the G2677 genotype in pediatric HTx patients.     

Hypothalamic knife cuts dissociate maternal behaviors, sexual receptivity, and estrous cyclicity in female hamsters

Female hamsters were tested for their response to pups as virgins, then received sagittal cuts either lateral to the medial preoptic area-medial anterior hypothalamus (anterior cuts) or lateral to the medial anterior hypothalamus-ventromedial nucleus (posterior cuts). Postoperatively females were tested: (a) as virgins, for changes in pup retrieval and cannibalism, (b) for mating behavior, (c) for maternal care and cannibalism of their own pups, and (d) for object hoarding. Anterior cuts converted retrieving virgins to cannibalistic ones and reduced nest builing. All females with anterior cuts cannibalized their litters within a few days of parturition. Half of these females did retrieve pups in home cage tests during the first 3 days postpartum. However, unlike controls, when tested in a neutral arena 5–6 weeks later, no pup retrieval was seen, although most would hoard objects. In contrast, posterior cuts reduced pup retrieval and cannibalism in virgins, and disrupted object hoarding. These cuts did not reduce postpartum pup retrieval, but did reduce postpartum cannibalism. Anterior cuts did not reduce sexual receptivity; posterior cuts reduced sexual receptivity without eliminating ovulation. Anterior cuts are interpreted as having a somewhat selective effect of reducing maternal responsiveness by cutting the lateral connections of neurons in the medial anterior hypothalamus and adjacent medial preoptic area, while posterior cuts disrupt sexual receptivity by cutting lateral connections of the ventromedial hypothalamus which travel in the region of the supraoptic commissures     

Gene-based strategies for the immunotherapy of cancer

 T lymphocytes play a crucial role in the host’s immune response to cancer. Although there is ample evidence for the presence of tumor-associated antigens on a variety of tumors, they are seemingly unable to elicit an adequate antitumor immune response. Modern cancer immunotherapies are therefore designed to induce or enhance T cell reactivity against tumor antigens. Vaccines consisting of tumor cells transduced with cytokine genes in order to enhance their immunogenicity have been intensely investigated in the past decade and are currently being tested in clinical trials. With the development of novel gene transfer technologies it has now become possible to transfer cytokine genes directly into tumors in vivo. The identification of genes encoding tumor-associated antigens and their peptide products which are recognized by cytotoxic T lymphocytes in the context of major histocompatibility complex class I molecules has allowed development of DNA-based vaccines against defined tumor antigens. Recombinant viral vectors expressing model tumor antigens have shown promising results in experimental models. This has led to clinical trials with replication-defective adenoviruses encoding melanoma-associated antigens for the treatment of patients with melanoma. An attractive alternative concept is the use of plasmid DNA, which can elicit both humoral and cellular immune responses following injection into muscle or skin. New insights into the molecular biology of antigen processing and presentation have revealed the importance of dendritic cells for the induction of primary antigen-specific T cell responses. Considerable clinical interest has arisen to employ dendritic cells as a vehicle to induce tumor antigen-specific immunity. Advances in culture techniques have allowed the generation of large numbers of immunostimulatory dendritic cells in vitro from precursor populations derived from blood or bone marrow. Experimental immunotherapies which now transfer genes encoding tumor-associated antigens or cytokines directly into professional antigen-presenting cells such as dendritic cells are under evaluation in preclinical studies at many centers. Gene therapy strategies such as in vivo cytokine gene transfer directly into tumors as well as the introduction of genes encoding tumor-associated antigens into antigen-presenting cells hold considerable promise for the treatment of patients with cancer. Received: 20 January 1997 / Accepted: 17 February 1997